Odyssey Therapeutics files first 10-Q with $175.7M cash, runway into H2 2028

Filed June 17, 2026 · Period ending March 31, 2026 · ~1 min read

Key Changes

• high

  Lead candidate OD-001 achieved proof-of-concept in phase 2a for ulcerative colitis; OD-002 in IND-enabling studies. All other programs remain preclinical, placing commercialization years away.

  MD&A: Pipeline verify on EDGAR →
• high

  Cash position of $175.7M plus May 2026 IPO proceeds fund operations into second half of 2028. Company has accumulated $606.4M in losses and expects continued substantial losses requiring additional capital beyond 2028.

  MD&A: Liquidity verify on EDGAR →
• high

  Q1 FY2026 net loss of $38.3M essentially flat versus $38.4M prior year. Collaboration revenue dropped to zero from $1.9M as J&J obligations completed and Pfizer MTA expired.

  MD&A: Quarterly Results verify on EDGAR →